preview.NewsStand
 

Latest Announcements

Axios International, Inc. awarded Global Health Supply Chain Technical Assistance (GHSC-TA) Contract by USAID

May 18, 2015

Axios International Inc., a U.S. small business within the Axios group of companies, has been awarded the USAID GHSC-TA contract to provide technical assistance to improve the availability of health commodities in PEPFAR countries.

GHSC-TA aims to strengthen country supply systems and strategic collaboration to improve the long-term availability of health commodities across all health areas (e.g. malaria, family planning, HIV/AIDS, TB, maternal and child health, etc.). This contract will serve the health commodity technical assistance needs of USAID, other USG agencies, partner country governments, non-governmental organizations (NGOs) and other entities with the goal of meeting the evolving challenges in ensuring long-term availability of health commodities in public and private services worldwide.

Axios will lead a consortium of organizations, which includes Chemonics International, Inc., Abt Associates, Dimagi, Inc., Expertise France, Foundation for Professional Development, IMA World Health, Institute for Health Measurement, Medical Access Uganda Limited and Panagora Group.

The project will be managed by the AI Inc. Washington D.C. office.

For more information, click here or contact Furhana Wehelie, IDIQ GHSC TA Project Director at Furhana.Wehelie@axiosint.com.

Axios Leads Summit with UAE Red Crescent to Foster Collaboration Among Musanda Charity Partners

December 30, 2014

Axios Regional Operations Manager Anas Nofal led a summit on December 18th in Sharjah, United Arab Emirates with the UAE Red Crescent, a key supporter of Axios’ patient-support initiatives across the United Arab Emirates. The purpose of the event was to increase awareness of the Musanda Patient Assistance Program, for which the UAE Red Crescent is a current charity partner. The summit was attended by 30 social workers and 5 NGO representatives from across the UAE. It was the second event of its kind held this year as part of a series of events aimed to foster collaboration among Musanda’s charity partners. These events, which are sponsored by Novartis Oncology, are slated to continue in 2015. 

New Video Highlights Impact of the Viramune Donation Programme

December 01, 2014

In commemoration of World AIDS Day which took place on 1 December 2014, Axios International, in partnership with Boehringer Ingelheim, released a video sharing the experience of the Viramune Donation Programme (VDP) in Tanzania.

In 1999, single dose Nevirapine (NVP), researched and developed by Boehringer Ingelheim, was found to be effective at reducing transmission of HIV when administered to HIV-positive pregnant women at the onset of labor and to their infants within 72 hours of birth. The results came at a crucial time. It was within this context that Boehringer Ingelheim, in partnership with Axios International, initiated the Viramune® Donation Programme (VDP) in 2000 to provide single dose Nevirapine (brand name Viramune®) free of charge to low-income countries. Between 2000-2013, the program provided Nevirapine free of cost to more than 2.3 million mother-child pairs across 164 institutions in 60 low and middle income countries to help prevent mother-to-child transmission of HIV.

Following new guidelines issued by the World Health Organization (WHO) in 2010 in response to the availability of new data and new treatment regimens replacing single-dose NVP with longer courses of antiretroviral therapy, VDP officially closed to new applications on December 31, 2013. The video focuses on the program’s impact in Tanzania and explores how the programme can be used as a model for future health interventions.

VDP LA Page2

 

 

 

 

 

 

 Click here to view the video. 

Axios CEO Meets with Patient’s Friends Committee (PFC) in United Arab Emirates to Discuss Expansion of Patient Assistance Programs

September 17, 2014

Axios CEO Dr. Joseph Saba and Regional Operations Manager Anas Nofal met with the Patients’ Friends Committee (PFC), a UAE-based charity that provides financial and educational assistance to patients who suffer from chronic diseases, to discuss the expansion of Axios’ patient assistance programs in the country. Among the support services discussed were financial aid to cover the cost of care and treatment for enrolled patients and patient education.

Read more on Al Khaleej

Axios Leads Capacity Building Workshop for Dubai Charity

September 10, 2014

Regional Operations Manager Anas Nofal led a workshop with social workers from the Patients Friends Committee, a Dubai-based charity, to introduce them to the Musanda program, a partial payment access program managed by Axios Gulf and supported by Novartis to increase access to high-quality medications. The program allows patients to only pay what they can afford for medications based on the results of a financial assessment. Local charities have also partnered with Axios to provide additional financial support for patients. The workshop focused on how Axios’ proprietary Patient Financial Eligibility Tool (PFET) is used to assess a patient’s ability to pay and the role of each charity in supporting patients enrolled in the program. The workshop was the first in a series of capacity building workshops sponsored by Novartis.   

Axios Publishes Assessment of HPV Vaccination Programs in 21 Programs across 14 Countries

July 03, 2014

Cervical cancer is the third most common cancer in women worldwide, with high incidence in lowest income countries. HPV vaccination may help to reduce the incidence of cervical cancer. Through the Gardasil Access Program (GAP), HPV vaccines were provided at no cost to help institutions gain experience implementing HPV vaccination. In this recently published assessment, Axios, the managers of GAP, examined the performance of 21 HPV vaccination programs implemented in 14 low and middle-income countries.

In order to evaluate the determinants of program performance and success, data on vaccine delivery model, number of girls vaccinated, number of girls completing the three-dose campaign, duration of vaccination program, community involvement and sensitization strategies were collected from each program upon completion. Vaccine Uptake Rate (VUR) and Vaccine Adherence between the first and third doses (VA) rate were also calculated. 

Community involvement in the follow-up of girls participating in the vaccination campaign was significantly associated with VUR. Multivariate analyses also identified school-based and health clinic models, NGO management (in close coordination with Ministries of Health) and duration of program vaccination as significant factors associated with VUR.

These results may be useful in the development of national HPV vaccination policies in low and middle-income countries.

To read the full article published in BMC Public Health, click here.

Dubai Health Authority

Axios Gulf partners with Dubai Health Authority (DHA)

April 10, 2014

Axios Gulf signs Memorandum of Understanding with the Dubai Health Authority (DHA). Joint agreement will be critical to the ongoing expansion of Axios’ efforts to drive access to quality healthcare and demonstrates DHA’s commitment to patients across the country. 

Read more on Al Khaleej and Al Bayan.  

HANDS Pakistan

Axios Partners with HANDS Organization in Pakistan

October 15, 2013

Given the growing need for patient assistance programs in Pakistan to increase patient access to quality medications, HANDS and Axios have partnered to better serve the needs of patients in the country. The two organizations will work together in the execution of Axios-managed patient assistance programs to coordinate patient assessments and any necessary additional social or financial support. 

HANDS is a Not-for-Profit Organization working since 1979 with key programs in health, education, poverty alleviation and disaster management. HANDS work reaches more than 25 million people in 42,000 villages in 29 districts of Pakistan. To read more about HANDS, clickhere

Pictured (left to right): Dr. Shaikh Tanveer Ahmed (Chief Executive Officer, HANDS), Anas Nofal (Regional Operations Manager, Axios) and Sami Sibai (Middle East Business Development Director, Axios)

Pharmaexec

Axios CEO sheds light on the booming commercial opportunity in Africa in the latest issue of Pharmaceutical Executive Magazine

August 01, 2013

Declining revenue growth in the United States and Europe have sent pharmaceutical companies in search of opportunities in the emerging economies of Latin America, the Middle East, and Asia. Now, as growth in these high-flying economies begins to stabilize, companies are finally turning their attention to Africa – a hidden trove of potential that is only as good as you make it. Written by Axios International’s Chief Executive Officer, Joseph Saba,  “New Rules for a New Africa” looks deeper at what makes the African pharmaceutical market unique, potential growth opportunities and tips to navigate this unique, heterogeneous market.

To read the full article, click here.

Educational Case Study on Market Access in China Published

July 18, 2013

The recently published case study from Ebru Tekinturhan, Strategy Director at Axios International, and Reinhard Angelmar, Emeritus Professor of Marketing at INSEAD, looks at approaches to increase access to a high-cost metastatic renal cell cancer therapy in China utilizing Axios’ Creative Access Strategies – a unique approach that allows patients to pay only what they can afford and allows pharmaceutical companies to gain access to new customers that they would otherwise not have reached through more traditional business approaches.

Titled "Patient Access to Rencell in China," the case study is intended to be used as a basis for class discussion. 

To purchase the case study, click here

To learn more about Creative Access Strategies, contact Joseph Saba at Joseph.Saba@axiosint.com. 

DSC03345

Dar El Ber Society partners with Axios International to support patients enrolled in a range of access programs across the UAE

June 04, 2013

These access programs have been developed to reach patients who may not be able to cover the full cost of their treatment for select chronic diseases.